U.S. FDA Approves TECVAYLI™ (teclistamab-cqyv), the First Bispecific T-cell Engager Antibody for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
I confess, I don't write very much anymore. So I'm using this post to spill all the beans, in no particular order. Take a break if y...
No comments:
Post a Comment